JP2018522579A - アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 - Google Patents

アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 Download PDF

Info

Publication number
JP2018522579A
JP2018522579A JP2018512825A JP2018512825A JP2018522579A JP 2018522579 A JP2018522579 A JP 2018522579A JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018522579 A JP2018522579 A JP 2018522579A
Authority
JP
Japan
Prior art keywords
seq
certain embodiments
levels
cell culture
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018512825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522579A5 (https=
Inventor
カッペリーニ マリア
カッペリーニ マリア
サング ヴィクトリア
サング ヴィクトリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2018522579A publication Critical patent/JP2018522579A/ja
Publication of JP2018522579A5 publication Critical patent/JP2018522579A5/ja
Priority to JP2021158571A priority Critical patent/JP2022023072A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
JP2018512825A 2015-05-20 2016-05-19 アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 Pending JP2018522579A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021158571A JP2022023072A (ja) 2015-05-20 2021-09-29 アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562164367P 2015-05-20 2015-05-20
US62/164,367 2015-05-20
US201662320032P 2016-04-08 2016-04-08
US62/320,032 2016-04-08
PCT/US2016/033187 WO2016187378A1 (en) 2015-05-20 2016-05-19 In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021158571A Division JP2022023072A (ja) 2015-05-20 2021-09-29 アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法

Publications (2)

Publication Number Publication Date
JP2018522579A true JP2018522579A (ja) 2018-08-16
JP2018522579A5 JP2018522579A5 (https=) 2019-06-27

Family

ID=57320751

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018512825A Pending JP2018522579A (ja) 2015-05-20 2016-05-19 アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法
JP2021158571A Pending JP2022023072A (ja) 2015-05-20 2021-09-29 アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021158571A Pending JP2022023072A (ja) 2015-05-20 2021-09-29 アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法

Country Status (8)

Country Link
US (2) US10548976B2 (https=)
EP (2) EP4190805A3 (https=)
JP (2) JP2018522579A (https=)
CN (1) CN108350057A (https=)
CA (1) CA2986432A1 (https=)
HK (1) HK1252174A1 (https=)
MA (1) MA42160A (https=)
WO (1) WO2016187378A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020193857A (ja) * 2019-05-28 2020-12-03 学校法人 東洋大学 熱中症マーカー及びその利用
JP2023518260A (ja) * 2020-03-20 2023-04-28 ケロス セラピューティクス インコーポレイテッド アクチビン受容体ｉｉ型キメラ及びその使用方法
JP2023529278A (ja) * 2020-04-28 2023-07-10 アクセルロン ファーマ インコーポレイテッド Ａｃｔｒｉｉタンパク質および後毛細管性肺高血圧症の処置における使用
JP2023534143A (ja) * 2020-06-23 2023-08-08 アクセルロン ファーマ インコーポレイテッド 肺動脈性肺高血圧症（ｐａｈ）の処置のためのａｃｔｒｉｉタンパク質

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
CN108350057A (zh) 2015-05-20 2018-07-31 细胞基因公司 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
WO2017079591A2 (en) * 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
NZ754161A (en) 2016-11-10 2025-11-28 Keros Therapeutics Inc Activin receptor type iia variants and methods of use thereof
CN110099995A (zh) * 2017-01-06 2019-08-06 奥林巴斯株式会社 细胞观察系统
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
US20230270821A1 (en) * 2020-11-06 2023-08-31 Acceleron Pharma Inc. Formulations comprising actrii polypeptide variants

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066486A2 (en) * 2012-10-24 2014-05-01 Celgene Corporation Biomarker for use in treating anemia

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009403A (pt) 1999-02-04 2001-11-27 Technion Res & Dev Foundation Método de expansão/conservação das células detronco hemopoiéticas indiferenciadas ou dascélulas progenitoras, método de preparação deum meio condicionado de célula estomacal útil naexpansão/conservação das células de troncohemopoiéticas indiferenciadas ou das célulasprogenitoras, método de transplante de célulasde tronco hemopoiéticas indiferenciadas ou decélulas progenitoras em um recipiente, tampão debiorreator e biorreator
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN104524548A (zh) 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
CN102131822A (zh) 2008-06-26 2011-07-20 阿塞勒隆制药公司 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
AU2010282361B2 (en) 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
EP3202459B1 (en) 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
AU2010315245B2 (en) 2009-11-03 2016-11-03 Acceleron Pharma Inc. Methods for treating fatty liver disease
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
KR20140084211A (ko) 2011-10-17 2014-07-04 악셀레론 파마 인코포레이티드 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물
HK1214504A1 (zh) 2012-10-24 2016-07-29 细胞基因公司 用於治療貧血的方法
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
EP3808778A1 (en) 2014-04-18 2021-04-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
US20180125928A1 (en) 2015-05-13 2018-05-10 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
CN108350057A (zh) 2015-05-20 2018-07-31 细胞基因公司 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3380121B1 (en) 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii antagonist for use in treating eye disorders
DK3496739T3 (da) 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
MA45811A (fr) 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
PL3638243T3 (pl) 2017-06-14 2025-02-10 Celgene Corporation Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066486A2 (en) * 2012-10-24 2014-05-01 Celgene Corporation Biomarker for use in treating anemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF HAEMATOLOGY, 2014. 165, 870-882, JPN6020018879, ISSN: 0004514489 *
EXPERIMENTAL HEMATOLOGY 2013;41:155-166, JPN6020018883, ISSN: 0004514490 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020193857A (ja) * 2019-05-28 2020-12-03 学校法人 東洋大学 熱中症マーカー及びその利用
JP7388679B2 (ja) 2019-05-28 2023-11-29 学校法人 東洋大学 熱中症マーカー及びその利用
JP2023518260A (ja) * 2020-03-20 2023-04-28 ケロス セラピューティクス インコーポレイテッド アクチビン受容体ｉｉ型キメラ及びその使用方法
JP2023529278A (ja) * 2020-04-28 2023-07-10 アクセルロン ファーマ インコーポレイテッド Ａｃｔｒｉｉタンパク質および後毛細管性肺高血圧症の処置における使用
JP7851259B2 (ja) 2020-04-28 2026-04-24 アクセルロン ファーマ インコーポレイテッド Ａｃｔｒｉｉタンパク質および後毛細管性肺高血圧症の処置における使用
JP2023534143A (ja) * 2020-06-23 2023-08-08 アクセルロン ファーマ インコーポレイテッド 肺動脈性肺高血圧症（ｐａｈ）の処置のためのａｃｔｒｉｉタンパク質
JP7854402B2 (ja) 2020-06-23 2026-05-01 アクセルロン ファーマ インコーポレイテッド 肺動脈性肺高血圧症（ｐａｈ）の処置のためのａｃｔｒｉｉタンパク質

Also Published As

Publication number Publication date
JP2022023072A (ja) 2022-02-07
US20180161426A1 (en) 2018-06-14
EP3298034A1 (en) 2018-03-28
CA2986432A1 (en) 2016-11-24
CN108350057A (zh) 2018-07-31
EP3298034A4 (en) 2019-02-13
US20200101157A1 (en) 2020-04-02
WO2016187378A1 (en) 2016-11-24
MA42160A (fr) 2018-03-28
EP4190805A3 (en) 2023-08-16
HK1252174A1 (zh) 2019-05-17
US10548976B2 (en) 2020-02-04
EP4190805A2 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US20200101157A1 (en) Vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
Hosui et al. Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation
Ohgami et al. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products
Forejtnikova et al. Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis
Imani et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling.
JP6501362B2 (ja) エリスロフェロンおよびｅｒｆｅポリペプチドならびに鉄代謝を調節する方法
JP2010531655A (ja) Ｃｘｃケモカイン受容体４（ｃｘｃｒ４）拮抗性ポリペプチド
US20040072259A1 (en) Methods and products for manipulating hematopoietic stem cells
Owen et al. Monocyte adherence to fibronectin: role of CD11/CD18 integrins and relationship to other monocyte functions
Dobashi et al. Growth hormone restores glucocorticoid‐induced T cell suppression
JP2025519561A (ja) Ｇｐｃｒ阻害剤及びその使用
Fox et al. Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature
US9375464B2 (en) HLA-G isoform for use in the treatment of a disease associated with bone resorption
Chakrabarti et al. Control of islet intercellular adhesion molecule-1 expression by interferon-α and hypoxia
Wang et al. Altered NCR3 splice variants may result in deficient NK cell function in renal cell carcinoma patients
JP6297552B2 (ja) Ｍｄｓの治療のための、ｃｄ９５シグナル伝達経路阻害剤
US20120201792A1 (en) Methods and products for manipulating hematopoietic stem cells
WO2020112642A1 (en) Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate
Socie Recent advances in paroxysmal nocturnal hemoglobinuria: from the biology to the clinic
WO2019099615A1 (en) Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth
US8349559B2 (en) System and method for identifying erythropoietin-responsive genes
US20070224181A1 (en) Arp as an Inducer of Granulocytopoiesis, Uses and Methods Thereof
Han et al. Proliferative capacity of single isolated CD34+ hematopoietic stem/progenitor cells in paroxysmal nocturnal hemoglobinuria
Shahcheraghi The pathophysiology of anti-Kell" hemolytic disease of newborn."
Menon ROLES FOR AN EPO-RECEPTOR PY343-STAT5 SIGNALING AXIS IN STRESS ERYTHROPOIESIS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210601

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210929

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20211012

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211012

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20211130

C032 Notice prior to dismissal

Free format text: JAPANESE INTERMEDIATE CODE: C032

Effective date: 20211221

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20211221